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Abstract: The complete genome of human cytomegalovirus (HCMV) was elucidated 
almost 25 years ago using a traditional cloning and Sanger sequencing approach. Analysis 
of the genetic content of additional laboratory and clinical isolates has lead to a better, 
albeit still incomplete, definition of the coding potential and diversity of wild-type HCMV 
strains. The introduction of a new generation of massively parallel sequencing 
technologies, collectively called next-generation sequencing, has profoundly increased the 
throughput and resolution of the genomics field. These increased possibilities are already 
leading to a better understanding of the circulating diversity of HCMV clinical isolates. 
The higher resolution of next-generation sequencing provides new opportunities in the 
study of intrahost viral population structures. Furthermore, deep sequencing enables novel 
diagnostic applications for sensitive drug resistance mutation detection. RNA-seq 
applications have changed the picture of the HCMV transcriptome, which resulted in proof 
of a vast amount of splicing events and alternative transcripts. This review discusses the 
application of next-generation sequencing technologies, which has provided a clearer 
picture of the intricate nature of the HCMV genome. The continuing development and 
application of novel sequencing technologies will further augment our understanding of 
this ubiquitous, but elusive, herpesvirus. 
Keywords: cytomegalovirus; genomics; transcriptomics; next-generation sequencing;  
drug resistance; deep sequencing 
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1. Introduction 
Human cytomegalovirus (HCMV), the prototype member of the herpesvirus subfamily 
Betaherpesvirinae, has a worldwide distribution and infections with this virus are extremely common. 
Seroprevalences in the adult population vary from 45% to 100%, increasing with age and varying with 
geographic location and socio-economic background [1]. HCMV causes only mild to no symptoms in 
immunocompetent individuals, but the virus is never cleared and establishes a latent infection for the 
lifetime of its host [2]. Primary infection, reactivation, or reinfection of immunocompromised 
individuals, such as transplant recipients and AIDS patients, results in considerable morbidity and 
mortality [3]. Furthermore, it is the most important congenital infection in both developed and 
developing countries, causing sensorineural hearing loss and neurodevelopmental delays [4].  
The double-stranded DNA (dsDNA) genome of wild-type HCMV strains has a size of around 235 kb, 
which is longer than all other human herpesviruses and one of the longest genomes of all human 
viruses in general. It has the characteristic herpesvirus class E genome architecture, consisting of two 
unique regions (unique long UL and unique short US), both flanked by a pair of inverted repeats 
(terminal/internal repeat long TRL/IRL and internal/terminal repeat short IRS/TRS). Both sets of 
repeats share a region of a few hundred bps, the so-called ―a sequence‖; the other regions of the 
repeats are sometimes referred to as ―b sequence‖ and ―c sequence‖ (Figure 1). The genome exists as 
an equimolar mixture of four genomic isomers by inversion of UL and US regions [5]. 
Figure 1. Class E genome of HCMV. The unique long and unique short regions are 
indicated as UL and US. Repeat regions are indicated as a, b and c sequences, where 
primes designate inverted orientations. Sequences ab and b’a’ correspond to the 
terminal/internal repeat long (TRL/IRL); sequences a’c’ and ca correspond to the 
internal/terminal repeat short (IRS/TRS). Top: typical genome arrangement of wild-type 
strains; bottom: genome arrangement of strain AD169 is given as an example of a 
laboratory-adapted strain. Genome rearrangements (deletion of UL 3‘ end and replacement 
by an inverted copy of UL 5‘ end) that have occurred during extensive passaging are 
indicated in red between the wild-type and laboratory-adapted configurations. 
 
The commercial introduction of new DNA sequencing technologies, referred to as next-generation 
sequencing (NGS), has immensely impacted the field of genomics. These novel technologies generate 
a massive throughput at a considerably lower per base cost than traditional Sanger sequencing, and 
obviate the need for laborious cloning procedures [6–8]. NGS has already shown its promise in 
virological research with applications in virus discovery and metagenomics, whole genome analysis, 
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deep sequencing of viral populations, novel diagnostic assays, and studies of virus-host interactions 
through transcriptome and epigenome studies [9–11]. In this review, we will highlight the recent 
progress that has contributed to the understanding of HCMV genomics through the application of  
NGS technologies. 
2. HCMV Genomics before the Introduction of NGS 
2.1. Genome Alterations during Cell Culture Adaptation  
When the first complete genome sequence of HCMV was published in 1990, it was the largest 
contiguous sequence generated at the time [12,13]. The authors estimated that the effort to sequence 
the genome of the laboratory-adapted strain AD169 with M13 shotgun cloning and Sanger sequencing 
was equivalent to a 12-year workload for one person. The laboratory-adapted strains AD169 and 
Towne had been passaged extensively in human fibroblast cell lines and were found to cause no or 
very low virulence in seronegative individuals during vaccine studies [14–16]. In contrast, the Toledo 
strain had been passaged significantly less and produced mononucleosis syndromes when administered 
to seropositive individuals [17]. When genome regions of AD169, Towne, and Toledo were compared 
through restriction enzyme profiles, hybridization, and sequencing techniques, it was observed that 
AD169 and Towne had lost genome segments of 15 kb and 13 kb, respectively. These segments were 
situated at the 3‘ end of the UL region (sometimes referred to as the UL/b‘ region) and were replaced 
by an inverted copy of the 5‘ end of the UL region, leading to an enlargement of the b repeats (Figure 1). 
This missing UL/b‘ segment was also found to be present in an additional set of five low-passage clinical 
isolates like Toledo, confirming that it is a universal hallmark of wild-type HCMV strains and clearly 
contains factors that are dispensable for fibroblast replication, but essential for virulence in vivo [18,19]. 
In addition to these genome rearrangements, strains AD169 and Towne display more subtle 
alterations of their coding capacity in genes inside—variants of AD169 and Towne with a more or less 
intact UL/b‘ region exist [20]—and outside the UL/b‘ region. AD169 has open reading frame (ORF) 
disrupting mutations in genes RL5A, RL13, UL36, and UL131A; Towne is affected in genes RL13, 
UL1, UL40, UL130, US1, and US9 [20–24]. Even the low-passage strain Toledo is mutated in genes 
RL13, UL9 and UL128 [25]. Almost all strains passaged in fibroblast cell cultures display one or more 
mutations in the UL128 locus (UL128L) and in the genes of the RL11 family, indicating a role in cell 
tropism for these gene products. UL128L consists of genes UL128, UL130, and UL131A (Figure 2). 
and its products form a complex with the viral glycoproteins gH and gL. While this complex is 
dispensable for growth in fibroblasts, it is essential for endothelial and epithelial cell tropism [26–28]. 
The RL11 gene family contains 14 genes at the 5‘ end of the UL region (RL5A, RL6, RL11-UL1, 
UL4-UL11, Figure 2) that are dispensable for growth in fibroblasts and are functionally poorly 
characterized [23,29,30]. Several of these genes show a remarkable genetic variability between 
different clinical isolates [25,31]. The majority of the RL11 genes have a characteristic domain 
(RL11D) that shares homology with the CR1 domain of the adenovirus E3 genes [23]. These proteins 
could function as modulators of a set of variable host proteins, and similarities to the immunoglobulin 
IgD family have been proposed [12]. Recently, some RL11 genes have indeed been implicated in 
immune evasive functions [32–34]. 
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Figure 2. Genome annotation of the low-passage HCMV strain Merlin (GenBank 
accession NC_006273). The dsDNA genome is visualized as a single line; nucleotide 
positions are given in bps. Terminal and internal repeat regions (TRL, IRL/IRS and TRS) 
are indicated with white boxes. Arrows represent genes; different gene families are 
designated with different color codes, as illustrated below the genome. The four large  
non-coding RNAs and the origin of lytic replication are also represented. 
 
While the consensus sequence of the low-passage strain Merlin only has a mutation in gene UL128, 
cloning of the strain into a bacterial artificial chromosome (BAC) vector showed that it was also 
defective in gene RL13 [25,35]. Since RL13 mutations were present at different sites in different 
clones, this was not noticeable in the consensus sequence. Repair of UL128 in the Merlin BAC 
repressed replication in fibroblast cells, but not in epithelial cells and, consequently, novel mutations 
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only emerged in fibroblasts. On the contrary, repair of RL13 impaired replication in fibroblast cells as 
well as in epithelial cells, and mutants appeared rapidly in both cell types. Mutational dynamics of 
clinical HCMV isolates were further analyzed in fibroblasts, epithelial, and endothelial cells by 
recording all mutations in four isolates up to passage 50 or more [36]. Several additional genes were 
mutated in some strains, but only UL128L and RL13 invariably mutated in fibroblast cells (RL13 in all 
cell types). Taken together, these studies stress the inherent instability of HCMV isolates when 
passaged in cell culture. Thus, in vitro studies with HCMV strains should allow for these limitations, 
and researchers should be mindful of the genetic changes that have altered the coding capacity and 
functionality of the strain under study. 
2.2. Genome Annotation  
The publication of the first complete genome sequence of HCMV was accompanied by a first 
genome annotation, predicting 208 ORFs that were potentially protein encoding [12]. Only ORFs 
encoding for proteins with a minimum length of 100 amino acids were considered, with a maximal 
overlap of 60% between ORFs. As the authors expected, this preliminary annotation wrongly predicted 
some ORFs and at the same time excluded genuine ORFs that were either too small or highly spliced. 
Since the results were based on the laboratory-adapted strain AD169, the ORFs encoded by the UL/b‘ 
region (Figure 1) were also missed [18,19]. The annotation was further refined by comparison with 
chimpanzee, rhesus and murine cytomegalovirus genomes [37,38] and by sequence analysis of 
additional clinical isolates of HCMV [25,39]. The low-passage strain Merlin has become the reference 
strain for wild-type HCMV, and its sequence entry (NCBI GenBank accession NC_006273, Table 1) 
currently contains a set of 170 genes. Several sets of genes share some sequence similarity and are 
thought to have originated from duplication events and subsequent divergence of structure and 
function [12,13]. These 15 gene families are indicated on the genome map in Figure 2. 
Table 1. HCMV complete genome sequences available on NCBI GenBank, listed in order 
of submission date. 
GenBank 
accession 
Strain name Clinical source Passage history Ref. 
Submission 
date 
X17403 AD169 Adenoids of a 7-year old girl 
Passaged extensively in 
human fibroblasts 
[12] 
December 6, 
1989 
BK00039’ AD169 varUK Adenoids of a 7-year old girl 
Passaged extensively in 
human fibroblasts 
[40] May 1, 2002 
NC_006273* 
GU179001 
Merlin 
Urine from a congenitally 
infected infant 
Passaged 3 times in human 
fibroblasts 
[25] 
September 27, 
2002 
AY315197 Towne varS 
Urine of a 2-month-old infant 
with microcephaly and 
hepatosplenomegaly 
Passaged extensively in 
human fibroblasts 
[30] June 6, 2003 
AC146851 Towne-BAC 
Urine of a 2-month-old infant 
with microcephaly and 
hepatosplenomegaly 
BAC clone from a plaque 
purified Towne derivative 
(varS) 
[39] 
October 14, 
2003 
AC146904 PH-BAC 
Transplant patient with 
HCMV disease 
BAC clone from isolate PH 
(passaged less than 12 times) 
[39] 
October 21, 
2003 
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Table 1. Cont. 
GenBank 
accession 
Strain name Clinical source Passage history Ref. 
Submission 
date 
AC146905 Toledo-BAC 
Urine from a congenitally 
infected infant 
BAC clone from a plaque 
purified Toledo derivative 
[39] 
October 21, 
2013 
AC146906 TR-BAC 
AIDS patient with CMV 
retinitis 
BAC clone from isolate TR [39] 
October 21, 
2013 
AC146907 FIX-BAC 
Cervical secretions of a 
pregnant woman with a 
primary HCMV infection 
BAC clone from isolate 
VR1814 
[39] 
October 21, 
2013 
AC146999 AD169-BAC Adenoids of a 7-year old girl 
BAC clone from a plaque 
purified AD169 derivative 
(varATCC) 
[39] 
October 31, 
2013 
EF999921 
TB40/E clone 
TB40-BAC4 
Throat wash of a bone marrow 
transplant recipient 
BAC clone from TB40/E 
passaged 5 times in human 
fibroblasts and 22 times in 
human endothelial cells 
[41] June 25, 2007 
FJ527563 AD169 varUC Adenoids of a 7-year old girl 
Passaged extensively in 
human fibroblasts 
[20] 
December 1, 
2008 
FJ616285 Towne varL 
Urine of a 2-month-old infant 
with microcephaly and 
hepatosplenomegaly 
Passaged extensively in 
human fibroblasts 
[20] 
January 9, 
2009 
GQ221973 HAN13 Bronchoalveolar lavage 
Passaged 3 times in human 
fibroblasts 
[42] May 28, 2009 
GQ221974 3157 
Urine from a congenitally 
infected infant 
Passaged 3 times in human 
fibroblasts 
[42] May 28, 2009 
GQ221975 JP 
Post mortem prostate tissue 
from an AIDS patient 
Unpassaged [42] May 28, 2009 
GQ396662 HAN38 Bronchoalveolar lavage 
Passaged 2 times in human 
fibroblasts 
[42] July 17, 2009 
GQ396663 HAN20 Bronchoalveolar lavage 
Passaged 2 times in human 
fibroblasts 
[42] July 17, 2009 
GQ466044 3301 
Urine from a congenitally 
infected infant 
Unpassaged [42] 
August 7, 
2009 
GU179288 U8 
Urine from a congenitally 
infected infant 
Unpassaged [42] 
November 5, 
2009 
GU179289 VR1814 
Cervical secretions of a 
pregnant woman with a 
primary HCMV infection 
Unpassaged [42] 
November 5, 
2009 
GU179290 U11 
Urine from a congenitally 
infected infant 
Unpassaged [42] 
November 5, 
2009 
GU179291 AF1 Amniotic fluid Unpassaged [42] 
November 5, 
2009 
GU937742 Toledo 
Urine from a congenitally 
infected infant 
Passaged several times in 
human fibroblasts 
[25] 
February 26, 
2010 
HQ380895 JHC 
Blood from a bone marrow 
transplant patient 
Plaque purified and 
passaged 3 times in human 
fibroblasts 
[43] 
October 7, 
2010 
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Table 1. Cont. 
GenBank 
accession 
Strain name Clinical source Passage history Ref. 
Submission 
date 
JX512197 6397 
Urine from a congenitally 
infected infant 
Passaged 3 times in human 
fibroblasts 
- 
August 21, 
2012 
JX512198 Davis 
Liver biopsy from a 
congenitally infected infant 
Passaged many times in 
human fibroblasts 
- 
August 21, 
2012 
JX512199 HAN1 Bronchoalveolar lavage No information - 
August 21, 
2012 
JX512200 HAN2 Bronchoalveolar lavage 
Passaged 3 times in human 
fibroblasts 
- 
August 21, 
2012 
JX512201 HAN3 Bronchoalveolar lavage 
Passaged 3 times in human 
fibroblasts 
- 
August 21, 
2012 
JX512202 HAN8 Bronchoalveolar lavage 
Passaged 3 times in human 
fibroblasts 
- 
August 21, 
2012 
JX512203 HAN12 Bronchoalveolar lavage 
Passaged 3 times in human 
fibroblasts 
- 
August 21, 
2012 
JX512204 HAN16 Urine from an infant 
Passaged 2 times in human 
fibroblasts 
- 
August 21, 
2012 
JX512205 HAN19 Bronchoalveolar lavage 
Passaged 2 times in human 
fibroblasts 
- 
August 21, 
2012 
JX512206 HAN22 Bronchoalveolar lavage 
Passaged 2 times in human 
fibroblasts 
- 
August 21, 
2012 
JX512207 HAN28 Bronchoalveolar lavage 
Passaged 3 times in human 
fibroblasts 
- 
August 21, 
2012 
JX512208 HAN31 Bronchoalveolar lavage 
Passaged 2 times in human 
fibroblasts 
- 
August 21, 
2012 
KC519319 BE/9/2010 Urine from an infant 
Passaged 2 times in human 
fibroblasts 
- 
January 23, 
2013 
KC519320 BE/10/2010 
Urine from a congenitally 
infected infant 
Passaged 2 times in human 
fibroblasts 
- 
January 23, 
2013 
KC519321 BE/11/2010 Urine from an infant 
Passaged 2 times in human 
fibroblasts 
- 
January 23, 
2013 
KC519322 BE/21/2010 
Urine from a pulmonary 
transplant recipient 
Unpassaged - 
January 23, 
2013 
KC519323 BE/27/2010 
Urine from a renal transplant 
recipient 
Passaged 4 times in human 
fibroblasts 
- 
January 23, 
2013 
KF021605 TR 
Vitreous humor from eye of 
HIV-positive male 
Passaged several times in 
human fibroblasts 
[44] May 9, 2013 
KF297339 
TB40/E clone 
Lisa 
Throat wash of a bone marrow 
transplant recipient 
Generated on human 
fibroblasts by passaging 
strain TB40/E once, plaque 
purifying 3 times and 
passaging once more 
[45] June 26, 2013 
°NCBI GenBank release file 199.0; search performed on 15 January 2014; patent sequences, transgenic strains, and 
incomplete sequences were not included; *NCBI Reference Sequence (RefSeq); ―Update from AD169 entry X17403 by 
the addition of the 929 bp missing region, encompassing UL42 and UL43, and the correction of sequencing errors. 
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2.3. Genetic Diversity 
Complete sequence analysis of several clinical isolates not only assisted the refinement of the 
genome annotation, but also led to the understanding that several regions of the HCMV genome are 
variable between different isolates [25,39]. Studies of individual gene sequences from viral 
glycoprotein genes [46–48], virulence-determining genes from the UL/b‘ region [49–51], and RL11 
genes [31,52,53] have been conducted to establish the existence of separate clusters of polymorphisms 
or genotypes (reviewed in [54–56]). Despite their variability, individual genotypes display remarkable 
sequence stability both within the host as in the population, and most genotypes seem to have a 
worldwide distribution [50,57–60]. Based on these data, it is hypothesized that the selective forces that 
have shaped the currently circulating genotypes were active during the evolution of early humans or 
even earlier and were modulated by founder and bottleneck events. In more recent times, migrations of 
human populations have redistributed and mixed these genotypes on a worldwide scale [56,59,61]. 
Furthermore, the very low incidence of gene linkage in the HCMV genome probably illustrates the 
predominant role of recombination in the generation of the existing genetic diversity [31,50,62–64]. 
The existence of distinct genotypes of several genes has attracted interest because of the potential 
differences in pathogenicity. If such correlations would be observed, this could provide novel 
diagnostic tools to tailor medical interventions. While some studies investigating genes UL55 
(glycoprotein B) [65,66], UL73 (glycoprotein N) [67,68], and UL144 (TNF-α-like receptor) [69–71] 
have presented data involving specific genotypes with different disease outcomes, there is no overall 
consensus on these correlations yet (reviewed in [54–56]). To establish the feasibility of using viral 
genotype data as prognostic markers in patient follow-up, more comprehensive studies that include 
larger sets of variable genes, if not complete genome sequences, will be necessary. In this regard, a 
study making use of gene sequences from only four genes (UL144, UL146, UL147 and US28) could 
train an artificial neural network to correctly predict congenitally-infected infants to be symptomatic or 
asymptomatic at birth in 90% of cases [72]. Considering the progress in sequencing technology and its 
implementation in HCMV genomics, this type of investigation should now become more feasible on a 
full genome scale. 
3. Characterization of Complete HCMV Genomes Using NGS 
Table 1 gives an overview of all complete HCMV genome sequences that are currently publicly 
available. If each individual strain is only counted once—some strains have multiple isolate sequences 
published—, this amounts to a total of 35 strains; 31 of these strains can be considered low-passage (or 
unpassaged) clinical isolates. While a considerable proportion of these sequences were still deduced 
using traditional Sanger sequencing, the labor intensity of these approaches precludes routine and 
high-throughput application of complete genome sequencing. Over the past 5 years, NGS technologies 
have begun to show their promise in becoming a novel, scalable, cost-effective, and time-efficient way 
of characterizing HCMV genome diversity. 
The first application of NGS to HCMV genomics was published in 2009 and investigated the 
genome architecture of laboratory-adapted strains AD169 and Towne in detail (Table 2) [20]. While 
the published sequences of AD169 (varUK and AD169-BAC/varATCC) and Towne (varS/varRIT3) 
Viruses 2014, 6 1057 
 
 
missed the entire UL/b‘ region (Table 1), it had already been noted that some variants did seem to 
contain this region [73,74]. For AD169, this variant constituted a separate stock (varUC), but it was 
unclear whether this was an AD169 variant with an intact UL/b‘ or a different strain altogether.  
For Towne, the original stock was a mixture of the varS/varRIT3 variant, that was cloned into a BAC 
and sequenced [30,39], and an apparently intact varL variant, for which the UL/b‘ region had been 
characterized [25]. The exact nature of the AD169 varUC stock and the mixed Towne stock containing 
both varS and varL was determined by generating sequencing reads with the Genome Analyzer 
(Illumina) and mapping these onto appropriate reference sequences with or without the UL/b‘ region. 
The results showed that AD169 varUC was indeed an AD169 variant with a nearly intact UL/b‘ 
region, only missing a 3.2 kb region affecting genes UL144, UL142, UL141, and UL140. Furthermore, 
the presence of both varS and varL variants in the Towne stock was experimentally confirmed. In a 
similar fashion, other studies have sequenced specific transgenic BAC clones of strains Merlin and 
Towne using NGS to characterize genetic changes that have occurred during passaging and cloning of 
these BACs (Table 2) [35,75,76]. 
Table 2. Overview of studies on the HCMV genome making use of NGS technology, 
ranked in chronological order. 
First author Title Journal 
NGS 
technology 
Ref. 
Publication 
date 
Bradley et al. 
High-throughput sequence analysis of variants of 
human cytomegalovirus strains Towne and AD169. 
J. Gen. Virol. IGA° [20] June 24, 2009 
Cunningham  
et al. 
Sequences of complete human cytomegalovirus 
genomes from infected cell cultures and clinical 
specimens. 
J. Gen. Virol. IGA° [42] 
November 11, 
2009 
Görzer et al. 
Deep sequencing reveals highly complex dynamics 
of human cytomegalovirus genotypes in transplant 
patients over time. 
J. Virol. GSF* [77] May 12, 2010 
Stanton et al. 
Reconstruction of the complete human 
cytomegalovirus genome in a BAC reveals RL13 to 
be a potent inhibitor of replication. 
J. Clin. Invest. IGA° [35] August 2, 2010 
Görzer et al. 
The impact of PCR-generated recombination on 
diversity estimation of mixed viral populations by 
deep sequencing. 
J. Virol. 
Methods 
GSF* [78] August 4, 2010 
Jung et al. 
Full genome sequencing and analysis of human 
cytomegalovirus strain JHC isolated from  
a Korean patient. 
Virus Res. GSF* [43] 
January 19, 
2011 
Renzette et al. 
Extensive genome-wide variability of human 
cytomegalovirus in congenitally infected infants. 
PLoS Pathog. IGA° [79] May 19, 2011 
James et al. 
Cyclopropavir inhibits the normal function of the 
human cytomegalovirus UL97 kinase. 
Antimicrob. 
Agents 
Chemother. 
IGA° [80] July 25, 2011 
Stark et al. 
High-resolution profiling and analysis of viral and 
host small RNAs during human  
cytomegalovirus infection. 
J. Virol. IGA° [81] 
October 19, 
2011 
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Table 2.Cont. 
First author Title Journal 
NGS 
technology 
Ref. 
Publication 
date 
Gatherer et al. 
High-resolution human cytomegalovirus 
transcriptome. 
Proc. Natl. 
Acad. Sci. U. 
S. A. 
IGA° [82] 
November 22, 
2011 
Bhattacharjee  
et al. 
Genetic analysis of cytomegalovirus in  
malignant gliomas. 
J. Virol. IGA° [83] April 11, 2012 
Meshesha et al. 
The microRNA Transcriptome of Human 
Cytomegalovirus (HCMV). 
Open Virol. J. IGA° [84] April 11, 2012 
Stern-
Ginossar et al. 
Decoding human cytomegalovirus. Science 
IGA°,  
HiSeq^ 
[85] 
November 23, 
2012 
Rossetto et al. 
Cis and trans acting factors involved in human 
cytomegalovirus experimental and natural  
latent infection of CD14 (+) monocytes and  
CD34 (+) cells. 
PLoS Pathog. MiSeq‘ [86] May 23, 2013 
Sahoo et al. 
Detection of cytomegalovirus drug resistance 
mutations by next-generation sequencing. 
J. Clin. 
Microbiol. 
GSJ‖ [87] August 28, 2013 
Renzette et al. 
Rapid intrahost evolution of human 
cytomegalovirus is shaped by demography and 
positive selection. 
PLoS Genet. IGA° [88] 
September 26, 
2013 
Brechtel et al. 
Complete Genome Sequence of a Cytomegalovirus 
Towne-BAC (Bacterial Artificial Chromosome) 
Isolate Maintained in Escherichia coli for 10 Years 
and Then Serially Passaged in Human Fibroblasts. 
Genome 
Announc. 
MiSeq‘ [75] 
September 26, 
2013 
Brechtel et al. 
Complete Genome Sequence of a UL96 Mutant 
Cytomegalovirus Towne-BAC (Bacterial Artificial 
Chromosome) Isolate Passaged in Fibroblasts To 
Allow Accumulation of Compensatory Mutations. 
Genome 
Announc. 
MiSeq‘ [76] 
October 24, 
2013 
° Genome Analyzer (Illumina); * 454 GS FLX (Roche); ^ HiSeq (Illumina); ‗ MiSeq (Illumina); ― 454 GS Junior (Roche). 
The previous studies made proper use of NGS technology to elucidate the stock composition of 
laboratory-adapted strains, but, then again, they could employ the existing sequence information to 
direct the assembly of the millions of sequencing reads that are generated during a typical Illumina run. 
In order to apply NGS to the genome characterization of novel clinical isolates, this assembly approach 
needed some adjustment. Because of the sequence variability in substantial regions of the HCMV 
genome, direct mapping of NGS reads from unknown isolates to existing reference sequences leads to 
a lack of coverage in these areas, simply because the novel sequences are too divergent from the 
chosen reference strain. To assemble the sequence information from novel clinical isolates, alternative 
approaches were devised that start with a de novo or reference-independent assembly of sequence 
reads (Table 2) [42]. The longer sequences formed by de novo assembly, the so-called contigs, are 
scaffolded against a reference sequence to produce a strain-specific reference that can be used for a 
mapping or reference-dependent assembly like before. The final strain sequence is optimized through 
manual inspection of the read alignment and correction of misassemblies by iterative mapping and/or 
PCR sequencing. 
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A comparative analysis was made of the effectiveness of sequencing complete HCMV genomes 
from clinical isolates through both Sanger sequencing of overlapping PCR products and NGS analysis 
of infected cell cultures and unamplified clinical material with the Genome Analyzer [42]. Both 
approaches were successful, but the PCR and Sanger sequencing method proved to be much more 
labor-intensive and, by consequence, less amenable to high-throughput application. However, the NGS 
approach is not specifically directed towards viral DNA and analyzes the total DNA present in an 
isolate. Whole cell culture extracts are heavily contaminated with cellular DNA and the viral loads in 
unamplified clinical material can be very low. This was illustrated for strain 3301 (Table 1); only 3% 
of sequence reads that were collected directly from the sample were of viral origin. While it was 
possible to reconstruct the complete genome using these 3% of reads, such an approach also precludes 
any high-throughput prospect. This limitation was recently confirmed when strain BE/21/2010 (Table 1) 
was amplified using undirected whole genome amplification and only yielded 12% HCMV-specific 
NGS reads (Sijmons et al, unpublished results). This study did realize higher levels of viral DNA 
(mostly >90%) by combining limited cell culture amplification, nuclease digestion of unencapsidated 
(cellular) DNA, purification of viral DNA, and whole genome amplification. A series of validation 
experiments showed that the generated genome sequences did not undergo major alterations during 
these procedures and were still representative for the strain in the original clinical isolate. 
As discussed previously, cell culture passaging leads to disruptive mutations in genes that are 
inhibitory or non-essential for growth in that cell type. Genes RL13 and UL128L seem to be the first 
that are affected when passaging a strain in fibroblast cells [35,36]. Interestingly, RL13 and UL128L 
genes do not show obvious disruptive mutations in most of the clinical isolates analyzed by NGS after 
limited culturing [42,43]. This suggests that these strains are still in a very early phase of genetic 
adaptation to fibroblast replication; although it cannot be ruled out that these genes are mutated at 
different sites in different clones of the population, like in the case of RL13 in strain Merlin [35]. 
Several observations imply that some ORF-disrupting mutations may be present in the original clinical 
isolate and are not an artifact of culturing [42]. Most importantly, the sequence characterization of 
strains JP and BE/21/2010 directly from clinical material (Table 1) has shown disruptive mutations in 
genes RL5A, UL9, UL111A, and UL150 that are definitely culture-independent. Furthermore, identical 
indels and point mutations were shared between unrelated isolates, which suggests that these could be 
derived from a common ancestor circulating in the human population. Finally, the presence of 
individual mutations in RL5A, UL1, UL9, and UL111A in passaged strains was confirmed by PCR 
sequencing of the original sample (Sijmons et al, unpublished results). Analysis of a larger number of 
clinical isolates will reveal the complete set of genes that can be disabled in clinical isolates, their 
occurrence in different patient populations, and potential implications for strain pathogenicity. 
4. Deep Sequencing of Intrahost HCMV Populations  
Accumulating data shows that infections with multiple HCMV strains are no exceptions, neither in 
immunocompromised nor in immunocompetent hosts (reviewed in [56]). This could probably be the 
product of both simultaneous and consecutive virus transmission events [89,90]. Multiple infections 
could result in a higher pathogenic potential because of trans-complementation between strains [91]. 
This prediction is confirmed by data about the effect of strain multiplicity in transplant patients [92–95]. 
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Because of the large amounts of sequence reads that are generated by NGS technologies, these are 
ideally suited to characterize the dynamics of mixed viral populations in greater depth (reviewed  
in [96,97]). The first study to apply this approach to HCMV populations analyzed PCR amplicons of 
the hypervariable genes UL73, UL74, and UL139 in lung transplant recipients using 454 GS FLX 
(Roche) technology (Table 2) [77]. Viral populations consisted of mixtures of up to six genotypes, 
with one or two types accounting for the majority of the population and the other genotypes present at 
frequencies of 0.1%–10%. When serial samples of patients were compared, the genotype frequencies 
fluctuated in a seemingly stochastic fashion. The authors speculated these fluctuations could be caused 
by sporadic and stochastic events that lead to differential reactivation of latent genomes. While the 
abundance of the individual genotypes changed, their sequences did not, confirming the stability of 
hypervariable HCMV genes [44,51,53]. In a follow-up study, the authors warned against the formation 
of artificial recombinants during PCR amplification when interpreting results from amplicon deep 
sequencing experiments [78]. 
The previous studies characterized intrahost population diversity by analyzing a set of genes that are 
highly variable between hosts. However, applying such a deep sequencing approach to a complete 
genome does not suffer from a selection bias towards certain genome regions and can provide a more 
comprehensive picture of the diversity and dynamics of viral populations inside the host. Sequencing 
complete genomes from unamplified clinical material, results in a low proportion of viral NGS reads, 
which would impair any deep sequencing effort [42]. Cell culture amplification on the other hand 
would almost certainly alter the composition of viral populations. Therefore, a workflow was devised 
that characterized complete HCMV genomes using overlapping PCR amplicons [79,83,88]. As an 
internal control, BAC clones of AD169 and Toledo strains were resequenced to establish a set of 
quality filtering thresholds that helped distinguishing genuine intrahost variants from PCR and 
sequencing errors. In a first study, the viral populations of three congenitally infected infants were 
characterized [79]. Surprisingly, for a dsDNA virus encoding a polymerase with proofreading capacity, 
estimates of the genetic diversity of these populations were comparable to quasispecies RNA viruses 
like HIV and dengue virus. Population variants were clustered in two groups. Variants present at high 
frequencies (≥90%) accounted for 20% of reads, while low-frequency variants (≤10%) represented 
73% of reads. This population structure is comparable to the study of UL73, UL74 and UL139 
amplicons in lung transplant recipients, which also found one or two variants present at higher 
frequencies and a set of low-frequency variants (0.1%–10%) [77]. Interestingly, when ORF-specific 
intrahost diversities were estimated, ORFs encoding glycoproteins or immune-evasive functions 
showed the lowest intrahost diversity estimates. While they are considered to have the highest interhost 
diversity, studies focusing on these ORFs may underestimate intrahost diversity. Compared to the 
results in congenitally infected infants, intrahost diversity estimates were lower in malignant gliomas [83]. 
A potential explanation for this discrepancy could be the higher levels of replication during congenital 
infection, which would lead to a higher accumulation of de novo mutations. More data from different 
patient groups is warranted to provide a broader view of the range of intrahost diversity estimates, the 
mechanisms that shape them, and potential implications for patient health. 
To better understand the dynamics of these genome populations, serial urine and plasma isolates 
were sampled from five infants with a symptomatic HCMV infection at birth [88]. When serial isolates 
of the same compartment were compared, the majority of SNPs had a similar frequency, and consensus 
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sequences differed only by 0.2% at the nucleotide level, demonstrating the overall stability of the 
populations. This result is in clear accordance with previous results that have illustrated the stability of 
HCMV genotypes in vivo [50,57,59]. However, comparison of isolates of different compartments 
(urine and plasma) at the same time point showed that consensus sequences differed by approx. 1%; 
comparable to the divergence of HCMV strains from different hosts. Subsequently, the observed 
dynamics were modeled using both demographic variables (population size and structure) and 
selective pressures. Intercompartment differentiation was shaped by strong bottleneck events and the 
calculation of bottleneck timing enabled estimation of the timing of infection and compartment 
colonization. While the effects of positive selection in the same compartment were small, strong 
evidence of positive selection was found when comparing different compartments. The large 
differences between viral populations in plasma and urine pose important questions about how 
representative the secreted virus (urine) is for the virus that circulates (plasma). It is conceivable that 
other compartments might show other diversification dynamics. However, the total number of patients 
analyzed in this study is relatively low and the data about intercompartment diversification are only 
based on one patient. From the presented data, it is unclear whether this patient was infected by a 
single strain or multiple strains. Rephrasing the issue: are we looking at the differentiation of one 
single quasispecies cloud or the segregation of multiple quasispecies clouds that could have had 
inherent differences in their respective cell tropisms? Analysis of the intercompartment diversity in 
additional patients will be needed to improve the understanding of the dynamics of these virus 
populations, which obviously could have very important implications for diagnostics, treatment, and 
vaccine development. 
The deep sequencing capabilities of NGS technology show great promise for the sensitive detection 
of drug resistance mutations. This approach has already proven its use in drug resistance testing for 
HIV, HCV, and HBV (reviewed in [10]). While Sanger sequencing of UL54 and UL97 PCR 
amplicons is still the gold standard for detection of drug resistance mutations in HCMV isolates, this 
method suffers from a lack of sensitivity, often failing when plasma viral loads drop below 1,000 
copies/mL and/or mutant frequencies are lower than 10%–20%. Recently, the use of NGS technology 
in resistance mutation detection was evaluated for the first time for HCMV [87]. Using the benchtop 
454 GS Junior system (Roche), the study showed the ability to reproducibly detect resistance 
mutations at frequencies lower than 20% and at viral loads lower than 1000 copies/mL. This 
improvement in sensitivity will help studying the abundance, dynamics, and importance of low-frequency 
drug-resistant variants. The high throughput of NGS could result in a decrease of the time and cost of 
resistance detection. In addition, full genome characterization of drug-resistant variants with NGS can 
potentially lead to the discovery of new resistance mutations in other genome regions. 
5. NGS in HCMV Transcriptome Studies 
The high throughput of NGS provided new opportunities for the field of transcriptomics; the study 
of the total coding and non-coding RNA that is transcribed in a given cell type [98]. NGS, often 
referred to as RNA-Seq in this context, has now surpassed microarrays as the method of choice for 
transcriptomic research, since it is much better at detecting rare variants and does not depend on a 
priori sequence knowledge. Transcriptomic analysis of HCMV in an infected cell can contribute to the 
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genome annotation by revealing complex transcriptional processes that often cannot be predicted based 
on the genome sequence alone. HCMV transcription is characterized by the presence of multiple 
transcripts sharing common 5‘ or 3‘ ends, complex and adaptable splicing patterns, antisense 
transcription, and transcription of non-coding and miRNAs (reviewed in [99]). Several NGS-based 
studies have added important insights into these processes. 
The first study to use RNA-Seq in HCMV transcriptome research characterized the polyA RNA 
content of human fetal foreskin fibroblast cells, 72h after infection with the Merlin strain, when virion 
production is underway [82]. The four large non-coding RNAs that are encoded in the HCMV genome 
(RNA2.7, RNA1.2, RNA4.9, and RNA5.0; Figure 2) accounted for a staggering 65.1% of viral 
transcription. These RNAs probably do not function via translation, since they do not overlap 
significantly with potential ORFs. Large non-coding RNAs are implicated in gene regulation in 
eukaryotes [100]. Especially RNA2.7 was transcribed massively, making up almost half of the viral 
transcripts. RNA2.7 inhibits apoptosis by regulation of mitochondria-induced cell death [101]. 
Furthermore, antisense transcripts were found throughout the genome, but are generally present at a 
lower level than their sense counterparts. Antisense transcription is increasingly being recognized as 
being involved in gene regulation, both in pro- and eukaryotes (reviewed in [102]). It can be 
hypothesized that the antisense transcripts of HCMV provide the virus with an additional mechanism 
of regulating its expression. Because of the high levels of transcription from non-coding and antisense 
regions, coding regions only made up one third of transcription. Within these coding regions, splicing 
patterns were found to be more numerous and complex than previously appreciated. While some of 
these splicing events are essential for proper expression, others probably have more subtle regulatory 
roles or could be non-functional by-products of normal transcription. Four new HCMV genes were 
identified based on this transcriptome study (RL8A, RL9A, UL150A, and US33A; Figure 2), 
indicating the added value of this kind of study for genome annotation. 
The added complexity that is caused by transcription and translation was further illustrated by a 
study that made use of a novel technique, i.e., ribosome profiling [85]. This technique characterizes the 
―translatome‖ by generating libraries of ribosome-protected mRNA fragments. Examining these 
ribosome footprints, the authors identified 751 ORFs, only 147 of which were previously recognized. 
ORFs were positioned within existing ORFs (both in-frame and out of frame), upstream of existing 
ORFs, antisense of existing ORFs, and within presumably non-coding regions. Multiple translation 
products were also identified on the long non-coding RNAs RNA2.7, RNA1.2, and RNA4.9. Tandem 
mass spectrometry and protein tagging experiments confirmed the translation of a large proportion of 
these novel ORFs. Furthermore, this study highlighted the use of alternative 5‘ ends, enabling the virus 
to express different proteins from overlapping coding regions in a temporally regulated fashion. 
The discovery that microRNAs (miRNAs), small RNAs that target and silence complementary 
mRNAs, are not restricted to eukaryotes, but also present in several viruses, including HCMV, added 
yet another weapon to the viral armory [103–107]. While miRNAs are non-immunogenic and only 
require minimal space in the genome, they offer the virus an efficient way of regulating both viral and 
host gene expression. Two studies have used NGS technology to characterize the profile of small 
RNAs that are expressed in HCMV-infected cells [81,84]. These studies used different HCMV strains 
(Towne vs. AD169), harvested RNA at different time points post-infection (72 h vs. 96 h), and 
assigned and verified novel miRNAs in different ways. The fraction of small RNAs encoding viral 
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miRNAs was 20% and 5%, respectively. The seven miRNAs with the highest expression levels were 
identical in both, although in a different order. While the second study identified more novel miRNAs 
from NGS data, the functionality of the only two novel miRNAs reported in the first study was 
confirmed in transfection assays. The first study also reported that all 22 characterized miRNAs were 
incorporated into the endogenous host silencing machinery, further highlighting their functionality [81]. 
Additionally, the authors identified novel small viral RNAs, distinct from miRNAs that were 
especially observed across the long non-coding RNAs, such as RNA2.7. These could be related to the 
ribosome footprints that were found on these RNAs [85]. 
Recently, the HCMV transcriptome of CD14+ and CD34+ cells in experimental and natural latency 
was characterized through deep sequencing, identifying transcripts that had not previously been related 
to latency [86]. These include UL44 and UL84 transcripts, normally involved in lytic DNA replication, 
and the large non-coding RNAs RNA2.7 and RNA4.9. 
In addition to providing insights into the viral expression profile during productive and latent 
infection, NGS-based transcriptome studies can also study the virus-host interface by simultaneously 
monitoring the changes in cellular transcription. Two studies have already illustrated this for murine 
cytomegalovirus, but similar studies on HCMV have not yet been published [108,109]. 
It has to be noted that the complex set of transcripts that were identified through deep sequencing 
still await further characterization to identify their potential functions. As the authors admit, some of 
the predicted RNAs and proteins could be aberrant byproducts of normal transcription/translation 
without further function and/or could be rapidly degraded [82,85]. These studies do offer the first 
glance at a complex regulatory network that the virus can use to finely balance its replication, 
including alternative splicing, antisense transcription, large and small non-coding RNAs, and miRNAs. 
6. Conclusions 
A quarter of a century has now passed since the publication of the first complete HCMV genome 
sequence ushered in the age of HCMV genomics. In the meantime, insights have accumulated 
regarding the genetic alterations of laboratory-adapted strains, the genome annotation has been 
progressively fine-tuned, and regions of high nucleotide diversity have been identified. The advent of 
NGS technology has changed the scope and pace of genomic research and is beginning to show its 
promise in the HCMV field. However, NGS is still a relatively recent technology and the interpretation 
of the massive amounts of sequence data requires considerable bioinformatics expertise. Error 
identification and correction protocols are not completely standardized yet and this precludes the 
routine application in clinical settings. 
Sequencing the complete genome of a clinical HCMV isolate is now possible in a considerably 
higher throughput and speed than a few years ago. Analysis of a large set of genomes from a diverse 
group of patients will improve our understanding of the circulating genetic diversity and variability in 
coding capacity of wild-type HCMV. This could lead to novel insights into the association of genetic 
diversity and viral pathogenicity, which has eluded the field for years. Furthermore, routine sequencing 
of transgenic strains to identify unintended genetic alterations should now be possible. 
Deep sequencing has shown that intrahost populations of HCMV are remarkably diverse. A better 
understanding of the dynamics of these populations could have important implications for treatment 
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and vaccine development. The sensitivity of NGS will also improve the standard of drug resistance 
mutation detection. 
RNA-Seq applications have already altered our understanding of the transcriptional complexity 
during HCMV-infection. Further characterization of these transcripts is warranted and could provide 
novel insights into mechanisms of viral pathogenicity and potential treatment options. Additionally, 
simultaneous characterization of the changes in the host transcriptome during infection will reveal 
currently unknown virus-host interactions. 
Meanwhile, a new generation of single-molecule sequencing technologies are being developed [110] 
or have already found their way to the market [111] (reviewed in [112]). These technologies require 
much less input material than NGS, making them more attractive for sequencing directly from clinical 
material. They do not need a library amplification step, ruling out possible artifacts caused by this step. 
Furthermore, they provide considerable longer read lengths, which facilitate genome assembly and 
could provide insights into the mutual relations of single variants in intrahost populations. Finally, 
these technologies can characterize DNA modifications, enabling the direct analysis of epigenetic 
changes in the genome [113,114]. Undoubtedly, application of single-molecule sequencing to HCMV 
genomics will aid in deciphering this complex herpesvirus. 
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